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As the number of fully sequenced animal genomes and the performance of advanced mass spectrometry-
based proteomics techniques are continuously improving, there is now a great opportunity to increase
the knowledge of various animal proteomes. This research area is further stimulated by a growing in-
terest from veterinary medicine and the pharmaceutical industry. Cerebrospinal ﬂuid (CSF) is a good
source for better understanding of diseases related to the central nervous system, both in humans and
other animals.
In this study, four high-abundant protein depletion columns, developed for human or rat serum, were
evaluated for dog CSF. For the analysis, a shotgun proteomics approach, based on nanoLC-LTQ Orbitrap
MS/MS, was applied. All the selected approaches were shown to deplete dog CSF with different success. It
was demonstrated that the columns signiﬁcantly improved the coverage of the detected dog CSF pro-
teome. An antibody-based column showed the best performance, in terms of efﬁciency, repeatability and
the number of proteins detected in the sample. In total 983 proteins were detected. Of those, 801 pro-
teins were stated as uncharacterized in the UniProt database. To the best of our knowledge, this is the so
far largest number of proteins reported for dog CSF in one single study.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Animal proteomics is a ﬁeld of growing interest both from a
veterinary perspective [1–7] and in the ﬁeld of animal models
used to investigate human diseases [8–15]. In human medical re-
search there is an ever increasing amount of publications on CSF
analysis. Some articles focus on a speciﬁc disease but there are also
reports on large scale mapping of the human CSF proteome which
have resulted in up to 3081 identiﬁed proteins [16–20]. Animal
CSF studies are still relatively uncommon and involve mostly
model animals like rat and mouse [10–14,21–23]. Dog CSF is of
high clinical interest due to the fact that dogs, like humans, are
affected by e.g. epilepsy, brain tumors, inﬂammation in the brain
and other brain and neurological related diseases [24–26]. Dogs
have proven to be very good model animals for human Alzhei-
mer's disease and aging [27–29]. There are also dog models for
more rare diseases such as Hurler's syndrome, Sanﬁlippo syn-
dromes and Duchenne muscular dystrophy [30–32].
There are several challenges associated with CSF analysis. FirstB.V. This is an open access article u
(M. Ramström).of all, the protein concentration in CSF is relatively low (in humans
0.2–0.8 mg/mL) [33,34]. Secondly, the dynamic range of proteins
has been reported to be up to twelve orders of magnitude [16,35].
Another issue is the high concentration of abundant proteins like
albumin and immunoglobulins which constitute 50% and 15% of
the total human CSF protein content, respectively [36]. If trans-
ferrin is added to the list, more than 70% of the total protein
amount is already covered [33]. No established analytical method
can today fully cover the whole dynamic range of proteins that is
present in CSF or plasma/serum. Instead, there are several meth-
ods available to fractionate or remove proteins in the sample to
decrease the dynamic range [37–39]. So-called depletion columns
are constructed to remove the most abundant proteins from body
ﬂuids, in general from human plasma [33]. Existing columns are
based on antibodies, recombinant modiﬁed variants of antibodies
or other kinds of afﬁnity matrices, removing up to 20 proteins [40].
Even though the total protein concentration in human plasma is
100–200 times higher than in CSF [33], several depletion columns
have also successfully been applied on human CSF since many of
the high-abundant components are the same in both body ﬂuids
[34,41–43]. Another strategy to reduce the dynamic range is to use
enrichment approaches. A limiting factor, at least for CSF samples,
is that rather high protein concentrations are needed. Even if thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CSF [44,45].
Today, only 811 out of the 25,485 sequences in the UniProt dog
reference proteome (taxonomy Canis lupus familiaris (Taxon
identiﬁer: 9615)), are reviewed. This implies that most of the dog
proteome is based on homology studies to proteomes of other
species. Most of the proteomics research performed on samples
from dog is based on plasma or serum. There are, however, some
reports on dog urine, bronchoalveolar ﬂuid and follicular ﬂuid, but
studies on CSF are still very rare [46]. Mass spectrometry is the
overall mostly applied method in human CSF proteomics due to
good sensitivity and the large amount of data that can be extracted
from each sample. However, so far, the published mass spectro-
metry-based dog CSF studies are small in size. In one study, CSF
from healthy dogs were compared to CSF from dogs with me-
ningoencephalitis using 2D gel electrophoresis followed by ana-
lysis of interesting spots with MALDI-TOF MS. In total, 134 protein
spots were detected on the gels and from those gel spots, 36
proteins were identiﬁed with MALDI-TOF MS [47]. In another
MALDI MS-based proteomic study, CSF samples from dogs with
degenerative myelopathy were compared with a control group in a
search for potential biomarkers for the disease. In that study, the
authors only mention transthyretin as an interesting protein [48].
Besides mass spectrometry, there are some reports on dog CSF
samples performed with antibody-based technologies such as
Luminex technology, Western Blot or ELISA with a small number of
proteins studied [49–51].
Mass spectrometry-based methods optimized for protein ana-
lysis are often applicable in proteomics studies of samples from all
species. However, afﬁnity-based sample preparation methods
should be more species-dependent. To the best of the authors'
knowledge, no depletion columns have so far been developed to
process body ﬂuids from dog. Therefore, one important objective
of this study was to verify if some of the methods available for
other species could be used on dog CSF. Four different high-
abundant protein depletion columns developed for human or rat
plasma/serum samples (Table 1) were selected and evaluated with
respect to efﬁciency, repeatability and the number of detected
proteins prior to and after depletion. Two of the columns were
antibody-based spin columns, while the other two were gravity
columns based on either recombinant proteins or an afﬁnity li-
gand. Another goal of this study was to determine how much of
the dog CSF proteome that could be revealed using state-of-the-art
shotgun proteomics, based on high-resolution mass spectrometry
in combination with the preparation strategies used in the study.
We here present the largest number of proteins in dog CSF that
have been published to date.Table 1
A summary of different parameters for the high-abundant protein depletion columns th
Product name ProteoExtracts albumin/
IgG removal (Cat. no.
122642)
Seppros rat spin column
(Cat. no. SEP110)
Targeted proteins Albumin and IgG Albumin, IgG, ﬁbrinogen,
transferrin, IgM, haptoglo-
bin, alpha1-antitrypsin
Developed for Human serum/plasma Rat serum/plasma
Matrix Afﬁnity matix IgY antibodies
Recommended total
protein amount (μg)a
1300–3900 975–1300
CSF protein amount (μg) 120 120
Dilution buffer used (μL) 300 500
Re-usable No Yes
a Calculated with an approximated total protein content of 65 mg/mL and the volum2. Experimental
2.1. Chemicals and reagents
Acetonitrile (ACN), acetone, formic acid (FA), acetic acid (HAc),
methanol (MeOH) and sodium chloride (NaCl) were purchased
from Merck (Darmstadt, Germany). Ammonium bicarbonate
(NH4HCO3), urea, sodium dodecyl sulfate (SDS), dithiothreitol
(DTT) and iodoacetamide (IAA) were obtained from Sigma-Aldrich
(St. Louis, MO, USA). For the tryptic digestion, trypsin (sequence-
grade bovine pancreas 1418475, Roche diagnostic, Basel, Switzer-
land) was used. XT sample loading buffer and XT MOPS buffer
were acquired from BioRad Laboratories (Hercules, A, USA). Ul-
trapure water was prepared by Milli-Q water puriﬁcation system
(Millipore, Bedford, MA, USA).
2.2. Cerebrospinal ﬂuid sample
The dog CSF was collected through lumbar puncture from a
beagle that had to be euthanized at the Swedish National Veter-
inary Institute (SVA), Uppsala. A total of 9.5 mL dog CSF sample
was collected and centrifuged at 2000 g for 10 min at 4 °C to
remove any cells. The supernatant was collected and the sample
was divided into 400 mL aliquots and stored at 80 °C until use.
The sample was clear without any visual signs of blood con-
tamination. The owner had given permission to collect the sample
and to use the sample in research projects. The Swedish Board of
Agriculture conﬁrmed that no additional ethical permission was
required for performing this study.
2.3. Method optimization – high-abundant protein depletion
The high-abundant depletion columns were chosen due to
their different technical solutions to speciﬁcally immobilize pro-
teins, see Table 1. Seppros Rat Spin Column (Sigma-Aldrich, St.
Louis, MO, USA), based on chicken IgY antibodies [52,53] and
Multiple Afﬁnity Removal Spin Cartridge – Human 14 (MARS-
Hu14) (Agilent Technologies, Waldbronn, Germany) based on
rabbit polyclonal antibodies and afﬁbodies were re-usable spin
columns. The other two columns were single use gravity columns.
The ProteoExtracts (Calbiochem, Merck Millipore, Darmstadt,
Germany) column uses an afﬁnity ligand (not Cibacron based) to
remove albumin and Protein A for the removal of IgG. The Pro-
teaPrep (Protea Biosciences, Morgantown, USA) column uses re-
combinant proteins for the albumin and IgG depletion.
The volume of plasma/serum that the different columns could
handle according to the kit instructions varied between 8–60 μL.at were evaluated in the study.
ProteaPrep albumin and IgG
depletion sample prep (Cat.
no. SP-240)
Multiple afﬁnity removal spin cartridge – human
14 (MARS-Hu14) (Product no. 5188-6560)
Albumin and IgG Albumin, IgG, antitrypsin,IgA, transferrin, hap-
toglobin, ﬁbrinogen, alpha2-macroglobulin, al-
pha1-acid glycoprotein, IgM, Apolipo-protein AI,
apolipoprotein AII, complement C3 and
transthyretin
Human serum/plasma Human serum/plasma
Recombinant protein IgG and afﬁbodies
65–650 520–650
120 120
400 200
No Yes
e that the manufacturer recommended.
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lumes from 65 mL up to 3 mL or even more [34,41–43,54]. From a
dog, about 1 mL CSF per 5 kg body weight can safely be removed
[55]. Based on this, 400 mL dog CSF was chosen as a reasonable
volume to work with and still be able to use all methods in
replicate.
The CSF samples were dried in a SpeedVac system until com-
plete dryness and were then re-suspended in the buffer that was
included in each depletion kit. The smallest buffer volumes sug-
gested by the manufacturer were used. Each depletion columns
were run in four technical replicates, according to the manufac-
turer's instructions. The two antibody based columns were re-
usable and therefore a stripping buffer was included in those
columns. The ProteoExtracts and ProteaPrep columns were single
use columns and thus there was no stripping buffer included.
Therefore a stripping buffer was prepared using the dilution buffer
from Agilent with an addition of 2% SDS. After collection of the
ﬂow through fraction, the bound proteins were eluted, either with
the included stripping buffer or the 2% SDS buffer. The fractions
were split in two and one was acetone precipitated and the pre-
cipitate was dried. The other half was completely dried in a
SpeedVac system.
For the quantiﬁcation of the protein concentration, an in-house
validated method (Dot it Spot it protein assay kit, http://dot-it-
spot-it.com, Maple Stone AB, Uppsala, Sweden) was used. The
method has been thoroughly described by Berglund et al. [56].
2.4. Sample processing
2.4.1. In-solution tryptic digestion
An aliquot of 400 μL dog CSF sample corresponding to ap-
proximately 120 μg total protein was dried down in a SpeedVac
system and re-suspended in 50 μL digestion buffer (8 M urea and
0.4 M NH4HCO3). 5 μL of 45 mM DTT was added and the sample
was kept at 50 °C for 15 min to reduce the proteins. To irreversibly
carbamidomethylate the cysteines, 5 μL of 100 mM IAAwas added,
followed by 15 min incubation at room temperature in darkness.
After the incubation 290 mL 0.4 M NH4HCO3 was added to dilute
the urea to 1 M. Trypsin (∼4% w/w) was added and the sample
was incubated over night at 37 °C. A volume of 35 μL corre-
sponding to ∼12 μg protein of the tryptically digested sample was
desalted on a ZipTips C18 column (Merck Millipore). This aliquot
was completely dried in a SpeedVac system and was then re-
suspended in 20 μL 0.1% FA. The tip was activated by 510 μL of
100% ACN and equilibrated with 510 μL of 0.1% FA. Then the
sample was coupled to the matrix by 30 repeated cycles of 10 μL
sample loading. The tip was then washed with 510 μL 0.1% FA.
Finally the sample was eluted in 10 μL 80% ACN, 0.1% FA by 15
cycles of aspirating and dispensing. This was done twice and then
the sample was completely dried in a SpeedVac system. The
peptides were re-suspended in 20 μL of 0.1% FA in Milli-Q water
before they were analyzed on a nanoLC-LTQ-Orbitrap mass
spectrometer.
2.4.2. SDS-PAGE and in-gel tryptic digestion
The protein pellets were re-suspended in 12.5 mL of XT Sample
Loading Buffer (BioRad Laboratories) together with 27.5 mL Milli-Q
water and the samples were shaken until the pellets had been
dissolved. A volume of 5 mL of 45 mM DTT was added and samples
were heated for 5 min at 95 °C. Samples were cooled to room
temperature and 5 mL of 100 mM IAA was added and the tubes
were incubated in darkness for 15 min. Untreated CSF samples
were re-suspended in twice the volume. A volume of 25 μL with
approximately 10–15 μg of protein was loaded into each lane of an
18-well, 4–12% Bis–Tris Criterion XT Precast Gel (BioRad Labora-
tories). The electrophoresis was run at 200 V constant for 60 min(starting current 165–175 mA/gel, ﬁnal current 60–70 mA/gel) in
XT MOPS running buffer. Finally, the gels were stained by Coo-
massie blue R-250 (BioRad Laboratories) according to manufac-
turer's instructions and scanned with an Epson scanner (Epson
perfection 4990 photo). The gel lanes were cut in three pieces but
the effect of cutting the gel lanes in 10 pieces was also in-
vestigated. All gel pieces were placed in separate test tubes. The
gel slices were divided into smaller pieces (∼1 mm3) and de-
stained by washing in 25 mM NH4HCO3 and 100% ACN twice or
until sufﬁcient color had been removed. Then the slices were va-
cuum centrifuged in a SpeedVac system for 15 min, 10 mM DTT
was added and the samples were incubated at 50 °C for 1 h and
this was followed by 1 h incubation in 50 mM IAA at room tem-
perature in darkness. Once again, the slices were washed in
25 mM NH4HCO3 and 100% ACN and dried in SpeedVac for 15 min.
Tryptic digestion was done for 1 h at room temperature with
12.5 ng/mL trypsin dissolved in 25 mM NH4HCO3. After the 1 h
incubation, 25 mM NH4HCO3 was added to completely cover the
gel bands and the incubation proceeded overnight in darkness at
37 °C. The solution was transferred to a new test tube and the gel
slices were covered with a solution containing 60% ACN and 5% FA
and sonicated for 5 min. Then the solution was transferred to the
same test tube as the previous fraction and the samples were
completely dried in a SpeedVac system. The peptides were re-
suspended in 20 μL of 0.1% FA in Milli-Q water before they were
analyzed on a nanoLC-LTQ-Orbitrap mass spectrometer.
2.5. NanoLC-LTQ-Orbitrap-MS/MS analysis
An EASY-nLC II system (ThermoFischer Scientiﬁc) was used for
the on-line Nano-LC separations. 5 μL of the sample was loaded
onto a pre-column (EASY-Column, 2 cm, inner diameter 100 μm,
5 μm, C18-A1, ThermoFischer Scientiﬁc) at a maximum pressure of
280 bar. The peptides were then eluted onto to an EASY-column,
10 cm, inner diameter 75 μm, 3 μm, C18-A2 (ThermoFischer Sci-
entiﬁc), which was used for the separation. The separation was
performed at a ﬂow rate of 200 nL/min using mobile phase A
(Milli-Q water with 0.1% FA) and B (ACN with 0.1% FA). A 2-step
90 min gradient, 2% B up 50% B in 75 min followed by wash step of
100% B for 15 min was used. The EASY-nLC II system was con-
nected to a LTQ Orbitrap Velos Pro ETD mass spectrometer
(ThermoFischer Scientiﬁc) equipped with a nano-ﬂex ion source.
The spray voltage was set to 2.0 kV. The instrument was controlled
through Tune 2.6.0 and Xcalibur 2.1. The LTQ Orbitrap Velos Pro
ETD was operated in data dependent mode to automatically
switch between high-resolution mass spectrum and low resolu-
tion in the LTQ. The survey scan was preformed from m/z 400–
2000 at 100,000 resolution and the 10 most abundant ion peaks
were CID fragmented for each full scan cycle. The mass window for
precursor ion selection was set to 1.9 Th. Screening was done for
charge state þ2, þ3 and þ4 and the dynamic exclusion was set to
30 s. Normalized collision energy of 35%, activation time of 10 ms
and activation q of 0.25 were set for MS/MS. The fragments were
scan at “normal scan rate” in the low pressure cell of the ion trap
and detected with a secondary electron multiplier.
2.6. Data analysis
For protein identiﬁcation, Proteome Discoverer version 1.4.1.14
(ThermoFischer Scientiﬁc) was used and searches were performed
using Sequest HT. The searches were done against a dog reference
proteome without isoforms (taxonomy 9615) that was down-
loaded from www.uniprot.org (2013-08-23). The reference pro-
teome contained 29209 sequences. The parameters for the search
were set to: ﬁxed modiﬁcations: carbamidomethyl (C), variable
modiﬁcations: deamidated (N, Q) and oxidation (M), precursor
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maximum two missed cleavage sites. The S/N threshold was set to
1.5. The search results were validated using the Percolator algo-
rithm and an FDR of 5%. A minimum of 2 unique peptides per
protein was applied.3. Results and discussion
3.1. Evaluation of the selected depletion strategies for dog CSF
3.1.1. Removal of target proteins
The aim of this study was to evaluate the performances of four
strategies to remove abundant proteins from canine CSF, as po-
tential preparation steps in front of high-resolution mass spec-
trometry. Since there are no depletion columns available for body
ﬂuids from dog, it is important to establish if commercial deple-
tion columns developed for humans or rat could be functional
alternatives. Some characteristics of the methods are summarized
in Table 1. All four columns were easy to use. The two antibody-
based columns, Seppros rat and MARS-Hu14 were rather quick
(20–30 min) to run while the two columns based on gravity
(ProteoExtracts and ProteaPrep) had longer runtimes (1–2 h). An
amount of 400 μL dog CSF sample, corresponding to 120 mg
protein, was depleted in each run from four technical replicates.
After depletion, approximately 15–40 μg of total protein remained
in the samples, indicating that substantial portions (67–88%) of the
proteins had been removed. The ﬂow through and the bound
fractions from each preparation were loaded on SDS-PAGE (Fig. 1A
and B). Due to detergents and high salt concentrations in the
bound fractions, acetone precipitation was introduced as a clean-
ing step. The SDS-PAGE indicated good repeatability between the
technical replicates. All columns could, to variable extent, deplete
at least albumin (66 kDa) (Fig. 1A and B). Albumin was most efﬁ-
ciently removed by the MARS-Hu14 and the Seppros rat columns,
and least efﬁciently by the ProteoExtracts column. Transferrin
(80 kDa) is seen in the bound fractions for Seppros rat and MARS-
Hu14. Bands at 150 kDa give an indication of that intact IgG have
been depleted.
The SDS-PAGE lanes of three of the four technical replicates
were divided into three fractions, digested by trypsin and there-
after analyzed by LC–MS/MS. In Table 2A, the four different de-
pletion columns are listed together with their target proteins and
the corresponding Peptide Spectrum Matches (PSMs) for all
technical replicates of the ﬂow through and bound fractions. In
spectral counting, the number of identiﬁed PSMs for a certain
protein is assumed to give its relative abundance [57,58]. Here, we
considered this parameter a good general estimation of the re-
lative abundances in the samples under study. Immunoglobulins
are difﬁcult to handle, because there is limited information about
dog immunoglobulins in the UniProt database.Fig. 1. (A) SDS-PAGE of the ﬂow through fractions and (B) of the bound fractions of
ProteaPrep, V: MARS-Hu14. Lower-case letters represent protein bands for (a): albuminFor MARS-Hu14, 11 out of 14 target proteins were detected. Of
the 11 detected proteins, 9 had higher PSM values in the bound
fractions than in the ﬂow through fractions. The large differences
in PSMs between the ﬂow through and bound fractions also in-
dicate efﬁcient removal of albumin, transthyretin and apolipo-
protein AI. Both MARS-Hu14 and Seppros rat showed higher
protein scores for transferrin in the ﬂow through fractions than in
the bound fractions, which supports what was seen on SDS-PAGE.
For Seppros rat all targeted proteins were found, and albumin,
haptoglobin and alpha-1-antitrypsin showed higher or similar
PSMs in the bound fraction. Both ProteaPrep and ProteoExtracts
were solely constructed to capture human albumin and IgG and
both of them capture the corresponding canine proteins, but not
as efﬁciently as the two antibody-based columns. ProteoExtracts
is the only column that shows higher PSM numbers for albumin in
the ﬂow through fraction, which is in line with what was seen on
SDS-PAGE. Table 2B lists the ﬁndings correlated to the total
number of protein fragments identiﬁed as belonging to im-
munoglobulins. In total 27 protein fragments were found,
searching all MS runs. The two antibody-based columns per-
formed best of the tested columns with 12 out of 27 possible
protein fragments found in the bound fraction, but only 3 for
Seppros rat and none for MARS-Hu14 in the ﬂow through fraction.
ProteoExtracts also showed 12 protein fragments in the bound
fraction, but there were also 7 found in the ﬂow through fraction.
In conclusion, particularly the two antibody-based columns
were very capable of removing canine proteins. A few of the target
proteins could not be detected, but none of these are very abun-
dant in dog CSF. MARS-Hu14 was demonstrated to efﬁciently de-
plete the targeted proteins from dog CSF. However, the drawback
was that this column removed many additional proteins, as seen
both on SDS-PAGE (Fig. 1A) and in LC–MS/MS analysis (Table 3).
3.1.2. Protein identiﬁcation and investigation of repeatability
The total number of identiﬁed proteins prior to and after de-
pletion was determined and compared. To estimate the repeat-
ability, the CV of the total number of proteins for the 3 technical
replicates from the different preparations was calculated and the
total number of proteins identiﬁed in all experiments was de-
termined (Table 3). The fractions from Seppros rat and Pro-
teoExtracts gave approximately the same average number of de-
tected proteins, but Seppros rat showed better repeatability
compared to ProteoExtracts. MARS-Hu14 provided repeatable
results, but gave the lowest number of detected proteins in this
study. When comparing the CV-values, all columns had similar or
even better repeatability than the non-depleted CSF and both
Seppros rat and ProteoExtracts gave higher total number of
proteins. The bound fractions showed similar repeatability with
around 55% of the detected proteins found in all technical re-
plicates, but the total number of proteins varied. Importantly, it
was concluded that the evaluated depletion strategies do notthe dog CSF sample. I: Non-depleted CSF, II: ProteoExtracts, III: Seppros rat, IV:
(66 kDa), (b): transferrin (80 kDa) and (c): IgG (150 kDa).
Table 2A
A comparison of PSMs of the proteins that the different depletion columns were designed to capture (except immunoglobulins). Both the ﬂow through (FT) and the bound
(B) fractions are listed for the three technical replicates.
Description Accession Replicate 1 (FT) Replicate 2 (FT) Replicate 3 (FT) Replicate 1 (B) Replicate 2 (B) Replicate 3 (B)
ProteoExtracts
Serum albumin F2Z4Q6 3392 2930 3595 1702 1746 2976
Seppros rat
Serum albumin F2Z4Q6 1360 434 877 3177 3225 3089
Transferrin J9P430 2201 2039 1866 284 309 455
Haptoglobin P19006 20 2 6 121 123 118
Alpha 1-antitrypsin A1ILJ0 98 89 81 89 63 68
Fibrinogen beta and gamma chain F1PGS2 2 2
F1P8G0
ProteaPrep
Serum albumin F2Z4Q6 683 687 868 1243 2849 1111
MARS-Hu14
Serum albumin F2Z4Q6 496 321 263 6981 4913 3900
Alpha 1-antitrypsin A1ILJ0 30 29 49 102 123 63
Transferrin J9P430 1411 1315 1260 899 461 352
Haptoglobin P19006 29 34 33 145 171 160
Alpha-2-macroglobulin F6UME0 11 4 7 87 120 110
Apolipoprotein A-I F1PDJ5 14 13 10 185 191 178
C3 F1PIX8 367 395 433 120 130 120
Transthyretin E2R5U8 41 22 51 375 246 313
Fibrinogen Not present
Alpha1-acid glycoprotein Not present
Apolipo protein AII Not present
Table 2B
In total, 27 protein fragments possibly related to immunoglobulins were found,
searching all MS runs. The table lists the number of fragments found in the ﬂow
through and bound fractions for each depletion column. Note that the different
depletion columns were design to capture different number of immunoglobulins.
Flow through fraction (num-
ber of protein fragment
detected)
Bound fraction (number of
protein fragment detected)
ProteoExtracts
IgG 7 12
Seppros rat
IgG and IgM 3 12
ProteaPrep
IgG 6 4
MARS-Hu14
IgA, IgG and IgM None 12
Table 3
Total number of detected proteins and the repeatability of the different columns
evaluated in the study. The numbers are based on 3 technical replicates of the ﬂow
through and bound fractions for 4 different depletion columns and non-depleted
sample.
Preparation Average
number of
detected
proteins
CV, number
of detected
proteins (%)
Total number
of unique
proteins in all
replicates
Number of
proteins de-
tected in all
replicates
Non-depleted 167 21 211 111
ProteoExtracts FT 199 17 265 134
Seppros rat FT 205 9 258 156
ProteaPrep FT 167 10 209 123
MARS-Hu14 FT 151 10 184 118
ProteoExtracts
Bound
102 20 125 67
Seppros rat
Bound
104 4 136 76
ProteaPrep Bound 93 25 118 64
MARS-Hu14
Bound
72 9 87 51
Fig. 2. Number of proteins found in the mass spectrometry runs of ﬂow through
and bound fractions from four different depletion columns. I: ProteoExtracts, II:
Seppros rat, III: ProteaPrep, IV: MARS-Hu14. The white ﬁeld indicates proteins
found in the ﬂow through fraction and the light gray area is proteins detected in the
bound fraction. The intersection represents proteins found in both fractions. All
numbers are based on three merged replicates.
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forming the experiments on non-depleted dog CSF.
Fig. 2 shows Venn diagrams with a combination of proteinsfound in the ﬂow through and bound fractions for each deple-
tion column. For all columns, a rather large number of proteins
were detected in the bound fractions, but most of those proteins
were also found in the ﬂow through fractions. There are many
reports of non-speciﬁc binding related to protein depletion
[41,59–61] and the low PSM-values for many of the proteins in
the bound fractions support that. Recently, a shotgun study on
dog proteins was published, where three different depletion
columns developed to deplete human albumin and IgG were
tested. The authors found a lot of non-speciﬁcally bound
Fig. 3. A comparison of the number of proteins detected in non-depleted dog CSF samples versus CSF prepared with four different depletion columns (ﬂow through and
bound fractions). (A) All proteins detected in the samples and (B) proteins in the gel fractions of size 55–75 kDa. The white ﬁeld shows proteins only found in non-depleted
fraction and the light gray area represents proteins detected in the samples depleted by I: ProteoExtracts, II: Seppros rat, III: ProteaPrep and IV: MARS-Hu14. All numbers
are based on three merged replicates.
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the use of depletion columns for dog studies [59]. In the present
study, we investigated both the ﬂow through and bound frac-
tions, and from our experience, it can be very limiting to judge
the different depletion columns, solely based on proteins found
in the bound fraction. In many studies, there will be a gain from
using the depletion columns if additional proteins can be
identiﬁed in the sample. It would, however, not be advisable to
use depletion columns in quantitative studies.
In Fig. 3A, a comparison of the three technical replicates of non-
depleted samples and all the different fractions (ﬂow through and
bound) of each depletion column is presented. Once again, Sep-
pros rat and ProteoExtracts were the best performing columns
with a total of 320 proteins detected. As compared to the non-
depleted preparation, 113 and 109 unique proteins were detected,
respectively, which is 35% of the total number of detected pro-
teins in those combinations. The low number of extra proteins for
both ProteaPrep and MARS-14 is eye-catching, demonstrating that
protein depletion of dog CSF sample results in a substantial loss of
proteins using these columns. One major reason for using deple-
tion strategies is to enhance the detection of proteins of similar
sizes as the dominating ones, in this case albumin. The SDS-PAGE
were divided in three fractions by cutting one narrow band 55–
75 kDa and two larger fractions containing proteins 475 kDa and
o55 kDa, respectively. Fig. 3B shows the number of proteins
found in depleted versus non-depleted 55–75 kDa fractions. For all
evaluated columns, there were more proteins detected in the de-
pleted 55–75 kDa fractions than in the untreated fraction. The
result is especially pronounced for Seppros rat.
Altogether, our results demonstrate that high-abundant protein
depletion can be fulﬁlled with all the tested columns, but with
varying efﬁciency. Seppros rat and ProteoExtracts performed
much better regarding the total number of detected proteins
compared to the two other evaluated columns. Seppros rat was
the best performing column. In particular, the detection of proteins
of sizes around 65 kDa was enhanced using this column. If also
cost is considered and less repeatability could be accepted, Pro-
teoExtracts is an alternative.3.2. Additional fractionation of the SDS-PAGE as a tool for increased
protein detection
A pilot study was set up to get an indication of to what extent
more fractionation of the SDS-PAGE lanes would improve the total
protein output from this sample. Based on the results from Section
3.1, the gel lanes of the untreated, Seppros rat and ProteoExtracts
depleted samples were divided in 10 fractions each. As expected, the
number of proteins increased dramatically compared to the fractio-
nation in three regions (Table 3). Most proteins, 724, were detected
for the non-depleted sample. Seppros rat gave 516 proteins and
ProteoExtracts 496 proteins. Importantly, Seppros rat added 87 un-
ique proteins compared to the non-depleted sample and ProteoEx-
tracts add 54 proteins. There has to be more replicates run to es-
tablish the fact that the non-depleted sample gave the highest
number of proteins. However, we consider this beyond the scope of
this pilot study. In this study, 400 mL CSF sample was used in the
depletion step which is a volume that can be used clinically. In human
studies a lot more CSF sample have been used, e.g. Schutzer et al. [16],
that used 18 mL of pooled CSF for the depletion step or Guldbrandsen
et al. [18] that used 3 mL CSF for the depletion followed by a frac-
tionation of the gel in 83 fractions. Those studies resulted in many
more detected proteins but with much larger volumes and extensive
fractionation. The objective of this study was to try to get an easy way
of preparing the dog CSF samples that could also be used for larger
studies. Extensive fractionation will make it very labor-intensive to
run large studies and notably, the size of dogs can also be a limiting
factor. Using all approaches presented here, the study resulted in a
total of 983 detected proteins, applying Sequest, with at least two
peptides, see Supplementary Data, Table S1. The table includes 801
previously uncharacterized dog proteins based on homology studies
to other species, which means that only 182 of the detected proteins
had been manually annotated in the UniProt database. This is the
largest reported number of detected proteins in CSF from a single dog
and is considerably larger than the 36 proteins that were reported in
the dog CSF study done by Nakamura et al. [47].
A gene ontology (www.geneontology.org) annotation was per-
formed with the support of the Proteome Discoverer software.
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are classiﬁed as plasma membrane, cell surface or extracellular
proteins which is higher than reported for humans. A similar com-
parison for cytoplasm and nucleus give a more overlapping pattern
with about 10% for both compartments in both species. For the dog,
there is also a large quantity of proteins with no annotation, which is
probably due to the limited information about the dog proteome to
date. The results from the annotations are presented in Figs. S1
(cellular components), S2 (molecular functions) and S3 (biological
processes). The results are in line with what have been presented in
earlier studies on human and mouse CSF [11,16]. Among the detected
proteins, there were many that have been reported as brain speciﬁc
in human and mouse CSF studies [22,62,63], e.g. tubulin alpha-1A
chain, microtubule-associated protein 6, neuron-speciﬁc enolase,
brain acid soluble protein 1, ubiquitin carboxyl-terminal hydrolase
isozyme L1, fructose-bisphosphate aldolase C, 14-3-3 proteins, ephrin
type-A receptor 4, neurexin-3-alpha, major prion protein, glial ﬁ-
brillary acidic protein, myelin basic protein, creatine kinase B-type
and brain-speciﬁc angiogenesis inhibitor 2. The fact that many of the
proteins have been reported in human CSF studies shows that there
is a potential to do comparative studies based on the methods pre-
sented here.
Extensive fractionation showed to be a very good tool to get at
better coverage of the dog proteome. One drawback is that it is a
labor-intensive approach. A more efﬁcient method to reach a
speciﬁed population of proteins could be depletion of a selected
high-abundant protein in combination with SDS-PAGE, followed
by cutting out a small band. In this study, Seppros rat gave a
dramatic improvement of the coverage of proteins of similar size
as albumin. This could e.g. be used when selecting good peptide
candidates for targeted proteomic approaches.4. Conclusions
In this study, it was concluded that it is possible to use com-
mercially available depletion columns, primarily developed for
human or rat plasma/serum samples, to prepare dog CSF samples
with an improved coverage of the dog CSF proteome. Even if all
methods could deplete CSF samples, there were large differences
between the methods. Seppros rat was in our hands the overall
best performing depletion column with high numbers of detected
proteins and good repeatability. Seppros was also a very good
method, compared to the others, to get a better detection of pro-
teins of similar size as albumin. Gel fractionation proved to be an
effective approach to increase the number of detected proteins.
However, it has to be considered that increasing the number of
fractions adds substantial more work effort and time required for
the sample preparation, LC–MS/MS experiments and data analysis.
Altogether, we here demonstrate that the combination of high-
abundant protein depletion, gel fractionation, in-solution and in-
gel tryptic digestion followed by analyses with nanoLC-Orbitrap
MS/MS, allows for a comprehensive map of the dog CSF proteome
with a much larger coverage than published before. In total 983
proteins, were detected using all different preparations of the in-
vestigated dog CSF sample. Several of the detected proteins have
previously been reported as brain speciﬁc in human and mouse,
which shows that the methods applied in this study also could be
used in comparative studies between dog and humans/mouse.Author Contributions
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